Relevance of cytochrome P450 polymorphisms in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease

Current Pharmacogenomics

Volumn 4, Issue 1, 2006, Pages 47-56

  Kirsch, Christian ^a   Morgner, Andrea ^a   Miehlke, Stephan ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Cytochrome P450; Gastroesophageal reflux disease; Helicobacter pylori; Proton pump inhibitor

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; CYTOCHROME P450 3A4; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AREA UNDER THE CURVE; ASIAN; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; EUROPE; GASTROESOPHAGEAL REFLUX; GENETIC POLYMORPHISM; GENOTYPE; HEALING; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PEPTIC ULCER; POPULATION RESEARCH; PROTEIN SYNTHESIS INHIBITION; QUANTITATIVE ANALYSIS; REVIEW; STOMACH ACID SECRETION; STOMACH PH; TREATMENT OUTCOME;

HELICOBACTER; HELICOBACTER PYLORI;

EID: 33646175929     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016006776055365     Document Type: Review

References (94)

1. Adachi, K.; Katsube, T.; Kawamura, A.; Takashima, T.; Yuki, M.; Amano, K.; Ishihara, S.; Fukuda, R.; Watanabe, M. and Kinoshita, Y. (2000) CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment. Pharmacol. Ther. 14, 1259-1266.
2. Adachi, K.; Fujishiro, H.; Katsube, T.; Yuki, M.; Ono, M.; Kawamura, A.; Rumi, M. A.; Watanabe, M. and Kinoshita, Y. (2001) Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J. Gastroenterol. Hepatol. 16, 1191-1196.
3. Andersson, T. (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin. Pharmacokinet. 31, 9-28. Review.
4. Andersson, T.; Hassan-Alin, M.; Hasselgren, G.; Rohss, K. and Weidolf, L. (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. Clin. Pharmacokinet. 40, 411-426. Review.
5. Aoyama, N.; Tanigawara, Y.; Kita, T.; Sakai, T.; Shirakawa, K.; Shirasaka, D.; Kodama, F.; Okumura, K. and Kasuga, M. (1999) Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J. Gastroenterol. 34, 80-83.
6. Bayerdörffer, E.; Miehlke, S.; Lehn, N.; Mannes, G. A.; Sommer, A.; Höchter, W.; Heldwein, W.; Weingart, J.; Klann, H.; Simon, T.; Schmitt, W.; Bästlein, E.; Eimiller, A.; Hatz, R.; Dirschedl, P. and Stolte, M. (1995) Double blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 108, 1412-1417.
7. Bayerdörffer, E.; Neubauer, A.; Rudolph, B.; Thiede, C.; Lehn, N.; Eidt, S. and Stolte, M. (1995) Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. Lancet 345, 1591-1594.
8. Blaisdell, J.; Mohrenweiser, H.; Jackson, J.; Ferguson, S.; Coulter, S.; Chanas, B.; Xi, T.; Ghanayem, B. I. and Goldstein, J. A. (2002) Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12, 703-711.
9. Breuer, T.; Goodman, K. J.; Malaty, H. M.; Sudhop, T. and Graham, D. Y. (1998) How do clinicians practising in the US manage Helicobacter pylori related gastrointestinal diseases. Am. J. Gastroenterol. 93, 553-556.
10. De Morais, S. M. F.; Wilkinson, G. R.; Blaisdell, J.; Nakamura, K.; Meyer, U. A. and Goldstein, J. A. (1994) The major genetic defect responsible for the polymorphism of the S-mephenytoin metabolism in humans. J. Biol. Chem. 269, 15419-15422.
11. De Morais, S. M. F.; Wilkinson, G. R.; Blaisdell, J.; Meyer, U. A.; Nakamura, K. and Goldstein, J. A. (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol. Pharmacol. 46, 594-598.
12. Dojo, M.; Azuma, T.; Saito, T.; Ohtani, M.; Muramatsu, A. and Kuriyama, M. (2001) Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig. Liver Dis. 33, 671-675.
13. Dore, M. P.; Piana, A.; Atzei, A.; Are, B. M.; Mura, I.; Massarelli, A.; Maida, A.; Sepulveda, A. R.; Graham, D. Y. and Realdi, G. (1998) Amoxycillin resistance is one reason for failure of amoxycillin/ omeprazole treatment of Helicobacter pylori infection. Aliment. Pharmacol. Ther. 12, 635-639.
14. Egan, L. J.; Myhre, G. M.; Mays, D. C.; Dierkhising, R. A.; Kammer, P. P. and Murray, J. A. (2003) CYP2C19 pharmacogenetics in the clinical use of proton-pump inhibitors for gastro-oesophageal reflux disease: variant alleles predict gastric acid suppression, but not oesophageal acid exposure or reflux symptoms. Aliment. Pharmacol. Ther. 17, 1521-1528.
15. Fennerty, M. B.; Lieberman, D. A.; Vakil, N.; Magaret, N.; Faigel, D. O. and Helfand, M. (1999) Effectiveness of Helicobacter pylori therapies in a clinical practice setting. Arch. Intern. Med. 159, 1562-1566.
16. Ferguson, R. J.; De Morais, S. M.; Benhamou, S.; Bouchardy, C.; Blaisdell, J.; Ibeanu, G.; Wilkinson, G. R.; Sarich, T. C.; Wright, J. M.; Dayer, P. and Goldstein, J. A. (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J. Pharmacol. Exp, Ther. 284, 356-361.
17. Fuhr, U. and Jetter, A. (2002) Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions. Pharmazie 57, 595-601. Review.
18. Furuta, T.; Ohashi, K.; Kamata, T.; Takashima, M.; Kosuge, K.; Kawasaki, T.; Hanai, H.; Kubota, T.; Ishizaki, T. and Kaneko, E. (1998) Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer disease. Ann. Intern. Med. 129, 1027-1030.
19. Furuta, T.; Ohashi, K.; Kosuge, K.; Zhao, X. J.; Takashima, M.; Kimura, M.; Nishimoto, M.; Hanai, H.; Kaneko, E. and Ishizaki, T. (1999) CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65, 552-561.
20. Furuta, T.; Shirai, N.; Xiao, F.; Ohashi, K. and Ishizaki, T. (2001) Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin. Pharmacol. Ther. 70, 484-492.
21. Furuta, T.; Shirai, N.; Watanabe, F.; Honda, S.; Takeuchi, K.; Iida, T.; Sato, Y.; Kajimura, M.; Futami, H.; Takayanagi, S.; Yamada, M.; Ohashi, K.; Ishizaki, T. and Hanai, H. (2002) Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin. Pharmacol. Ther. 72, 453-460.
22. Furuta, T.; Shirai, N.; Takashima, M.; Xiao, F.; Hanai, H.; Nakagawa, K.; Sugimura, H.; Ohashi, K. and Ishizaki, T. (2001) Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 11, 341-348.
23. Furuta, T.; Shirai, N.; Takashima, M.; Xiao, F.; Hanai, H.; Sugimura, H.; Ohashi, K.; Ishizaki, T. and Kaneko, E. (2001) Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin, Pharmacol. Ther. 69, 158-168.
24. Furuta, T.; Shirai, N.; Xiao, F.; Takashita, M.; Sugimoto, M.; Kajimura, M.; Ohashi, K. and Ishizaki, T. (2003) High-dose rabeprazole/ amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology 50, 2274-2278.
25. Furuta, T.; Shirai, N.; Xiao, F.; El-Omar, E. M.; Ralikin, C. S.; Sugimura, H.; Ishizaki, T. and Ohashi, K. (2004) Polymorphism of interleukin-lbeta affects the eradication rates of Helicobacter pylori by triple therapy. Clin. Gastroenterol. Hepatol. 2, 22-30.
26. Furuta, T.; Shirai, N.; Sugimoto, M.; Nakamura, A.; Okudaira, K.; Kajimura, M. and Hishida, A. (2005) Effect of concomitant dosing of famotidine with lansoprazole on gastric acid secretion in relation to CYP2C19 genotype status. Aliment. Pharmacol. Ther. 22, 67-74.
27. Hokari, K.; Sugiyama, T.; Kato, M.; Saito, M.; Miyagishima, T.; Kudo, M.; Nishikawa, K.; Ishizuka, J.; Komatsu, Y.; Mizushima, T.; Kagaya, H.; Hige, S.; Takeda, H. and Asaka, M. (2001) Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment. Pharmacol. Ther. 15, 1479-1484.
28. Horai, Y.; Kimura, M.; Furuie, H.; Matsuguma, K.; Irie, S.; Koga, Y.; Nagahama, T.; Murakami, M.; Matsui, T.; Yao, T.; Urae, A. and Ishizaki, T. (2001) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment. Pharmacol. Ther. 15, 793-803.
29. Hu, Y.; Xu, J.; Mei, Q.; Xu, X. H. and Xu, S. Y. (2005) Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotype in healthy Chinese subjects. Acta Pharmacol. Sin. 26, 384-388.
30. Huang, J. Q. and Hunt, R. H. (1999) Treatment after failure: the problem of non-responders. Gut 45, 140-144.
31. Huber, R.; Kohl, B.; Sachs, G.; Senn-Bilfinger, J.; Simon, W. A. and Sturm, E. (1995) Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment. Pharmacol, Ther. 9, 363-378. Review
32. Hunt, R. H. and Thomson, A. B. R. (1998) Canadian Helicobacter pylori consensus conference. Can. J. Gastroenterol. 12, 31-41.
33. Ibeanu, G. C.; Blaisdell, J.; Ghanayem, B. I.; Beyeler, C.; Benhamou, S.; Bouchardy, C.; Wilkinson, G. R.; Dayer, P.; Daly, A. K. and Goldstein, J. A. (1998) An additional defective allele CYP2C19*5, contributes to the S-mephenytoin poor metabolizer genoptype in Caucasian. Pharmacogenetics 8, 129-135.
34. Ibeanu, G. C.; Goldstein, J. A.; Meyer, U.; Benhamou, S.; Bouchardy, C.; Dayer, P.; Ghanayem, B. I. and Blaisdell, J. (1998) Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J. Pharmacol. Exp. Ther. 286, 1490-1495.
35. Ibeanu, G. C.; Blaisdell, J.; Ferguson, R. J.; Ghanayem, B. I.; Brosen, K.; Benhamou, S.; Bouchardy, C.; Wilkinson, G. R.; Dayer, P. and Goldstein, J. A. (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J. Pharmacol. Exp. Ther. 290, 635-640.
36. m2 in exon 4, in Japanese subjects. Clin. Pharmacol. Ther. 59, 647-653.
37. Inaba, T.; Mizuno, M.; Kawai, K.; Yokota, K.; Oguma, K.; Miyoshi, M.; Take, S.; Okada, H. and Tsuji, T. (2002) Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J. Gastroenterol. Hepatol. 17, 748-753.
38. Inamori, M.; Togawa, J.; Takahashi, K.; Yoneda, M.; Fujisawa, N.; Iwasaki, T.; Ozawa, Y.; Kikuchi, T.; Muramatsu, K.; Chiguchi, G.; Matsumoto, S.; Kawamura, H.; Abe, Y.; Kirikoshi, H.; Kobayashi, N.; Sakaguchi, T.; Takamura, T.; Nakajima, A.; Ueno, N. and Sekihara, H. (2003) Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? J. Gastroenterol. Hepatol. 18, 1034-1038.
39. Ishizaki, T. and Horai, Y. (1999) Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment. Pharmacol. Ther. 13, 27-36. Review.
40. Ishizaki, T.; Sohn, D. R.; Kobayashi, K.; Chiba, K.; Lee, K. H.; Shin, S. G.; Andersson, T.; Regardh, C. G.; Lou, Y. C. and Zhang, Y. (1994) Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther. Drug. Monit. 16, 214-215.
41. Isomoto, H.; Inoue, K; Furusu, H.; Nishiyama, H.; Shikuwa, S.; Omagari, K.; Mizuta, Y.; Murase, K.; Murata, I. and Kohno, S. (2003) Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 8, 111-119.
42. Isomoto, H.; Inoue, K.; Furusu, H.; Enjoji, A.; Fujimoto, C.; Yamakawa, M.; Hirakata, Y.; Omagari, K.; Mizuta, Y.; Murase, K.; Shimada, S.; Murata, I. and Kohno, S. (2003) High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection. Aliment. Pharmacol. Ther. 18, 101-107.
43. Kale-Pradhan, P. B.; Landry, H. K. and Sypula, W. T. (2002) Esomeprazole for acid peptic disorders. Ann. Pharmacother. 36, 655-663. Review.
44. Kaneko, A.; Kaneko, O.; Taleo, G.; Bjorkman, A. and Kobayakawa, T. (1997) High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 29, 921-922.
45. Katsube, T.; Adachi, K.; Kawamura, A.; Amano, K.; Uchida, Y.; Watanabe, M. and Kinoshita, Y. (2000) H. pylori infection influences nocturnal acid breakthrough. Aliment. Pharmacol. Ther. 14, l049-1056.
46. Kawabata, H.; Habu, Y.; Tomioka, H.; Kutsumi, H.; Kobayashi, M.; Oyasu, K.; Hayakumo, T.; Mizuno, S.; Kiyota, K.; Nakajima, M.; Kimoto, K.; Inokuchi, H. and Kawai, K. (2003) Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment. Pharmacol. Ther. 17, 259-264.
47. Kawamura, M.; Ohara, S.; Koike, T.; Iijima, K.; Suzuki, J.; Kayaba, S.; Noguchi, K.; Hamada, S.; Noguchi, M. and Shimosegawa, T. (2003) Study Group of GERD. The effects of lansoprazole on erosive reflux esophagitis are influenced by CYP2C19 polymorphism. Aliment. Pharmacol. Ther. 17, 965-973.
48. Kita, T.; Tanigawara, Y.; Aoyama, N.; Hohda, T.; Saijoh, Y.; Komada, F.; Sakaeda, T.; Okumura, K.; Sakai, T. and Kasuga, M. (2001) CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm. Res. 18, 615-621.
49. Klotz, U.; Schwab, M. and Treiber, G. (2004) CYP2C19 polymorphism and proton pump inhibitors. Basic. Clin. Pharmacol. Toxicol. 95, 2-8. Review.
50. Laheij, R. J.; Rossum, L. G.; Jansen, J. B.; Straatman, H. and Verbeek, A. L. (1999) Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment. Pharmacol. Ther. 13, 857-864.
51. Lam, S. K. and Talley, N. J. (1998) Helicobacter pylori consensus: report of the 1997 Asia Pacific consensus conference on the management of Helicobacter pylori infection. J. Gastroenterol. Hepatol. 13, 1-12.
52. Lee, S. B.; Park, S. J.; Ryu, J. K.; Lee, J. K.; Kim, H. J.; Bae, J. S.; Jung, H. S. and Park, S. M. (2003) Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J. Gastroenterol. 42, 468-475.
53. Lin, C. J.; Yang, J. C.; Uang, Y. S.; Chern, H. D. and Wang, T. H. (2003) Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 3, 711-719.
54. Malfertheiner, P.; Megraud, F.; O'Morain, C.; Hungin, A. P.; Jones, R.; Axon, A.; Graham, D. Y. and Tytgat, G. (2002) The European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 16, 167-180. Review
55. Meyer, U. A. (1996) Metabolic interactions of the proton pump-inhibitors lansoprazole, omeprazole and pantoprazole with other drugs. Eur. J. Gastroenterol. Hepatol. 8, 21-25. Review.
56. Miehlke, S.; Madisch, A.; Kirsch, C.; Lindner, F.; Kuhlisch, E.; Laass, M.; Knoth, H.; Morgner, A. and Labenz, J. (2005) Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily - a randomised, two-way crossover study. Aliment. Pharmacol. Ther. 21, 963-967.
57. Miehlke, S.; Mannes, G. A.; Lehn, N.; Bayerdörffer, E.; Hele, C. and Stolte, M. (1997) An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively. Aliment. Pharmacol. Ther. 11, 323-329.
58. Miehlke, S.; Madisch, A.; Kirsch, C.; Lindner, F.; Kuhlisch, E.; Laass, M.; Knoth, H.; Morgner, A.; Labenz, J. (2005) Intragastric acidity during treatment with esomeprazole 40 mg twice daily and pantoprazole 40 mg twice daily - a randomized, two-way crossover study. Aliment. Pharmacol. Ther. 21, 963-967.
59. Miki, I.; Aoyama, N.; Sakai, T.; Shirasaka, D.; Wambura, C. M.; Maekawa, S.; Kuroda, K.; Tamura, T.; Kita, T.; Sakaeda, T.; Okumura, K. and Kasuga, M. (2003) Impact of clarithromycin resistance and CYP 2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur. J. Gastroenterol. Hepatol. 15, 27-33.
60. Miner, P. Jr.; Katz, O.; Chen, Y. and Sostek, M. (2003) Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole: A five-way crossover study. Am. J. Gastroenterol. 98, 2616-2620.
61. Miyoshi, M.; Mizuno, M.; Ishiki, K.; Nagahara, Y.; Maga, T.; Torigoe, T.; Nasu, J.; Okada, H.; Yokota, K.; Oguma, K. and Tsuji, T. (2001) A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J. Gastroenterol. Hepatol. 16, 723-728.
62. Ohkusa, T.; Maekawa, T.; Arakawa, T.; Nakajima, M.; Fujimoto, K.; Hoshino, E.; Mitachi, Y.; Hamada, S.; Mine, T.; Kawahara, Y.; Nagai, T.; Aoyama, N.; Yoshida, N.; Tadokoro, K.; Chida, N.; Konda, Y.; Seno, H.; Shimatani, T.; Inoue, M. and Sato, N. (2005) Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment. Pharmacol. Ther. 21, 1331-1339.
63. Ours, T. M.; Fackler, W. K.; Richter, J. E. and Vaezi, M. F. (2003) Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am. J. Gastroenterol. 98, 545-550.
64. Pearce, R. E.; Rodrigues, A. D.; Goldstein, J. A. and Parkinson, A. (1996) Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277, 805-816.
65. Peghini, P. L.; Katz, P. O.; Bracy, N. A. and Castell, D. O. (1998) Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am. J. Gastroenterol. 93, 763-767.
66. Peghini, P. L.; Katz, P. O. and Castell, D. O. (1998) Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 115, 1335-1339.
67. Rebbeck, T. R.; Jaffe, J. M.; Walker, A. H.; Wein, A. J. and Malkowicz, S. B. (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4 [published en-aturn appears in J. Natl. Cancer Inst. (1999), 91, 1082]. J. Natl. Cancer. Inst. 90, 1225-1229.
68. Peura, D. A. and the American Digestive Health Foundation (1997) The report of the Digestive Health Initiative international upgrade conference on Helicobacter pylori. Gastroenterology 113, 4-8.
69. Roh, H. K.; Dahl, M. L.; Tybring, G.; Yamada, H.; Cha, Y. N. and Bertilsson, L. (1996) CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 6, 547-551.
70. Roh, H. K.; Kim, P. S.; Lee, D. H.; Tybring, G.; Sagar, M.; Park, C. S.; Seensalu, R. and Bertilsson, L. (2004) Omeprazole treatment of Korean patients: Effects on gastric pH and gastrin release in relation to CYP2C19 geno- and phenotypes. Basic Clin. Pharmacol. Toxicol. 95, 112-119.
71. +ATPase. Ann. Rev. Pharmacol. Toxicol. 35, 277-305. Review.
72. Sagar, M.; Tybring, G.; Dahl, M. L.; Bertilsson, L. and Seensalu, R. (2000) Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 119, 670-676.
73. Saitoh, T.; Fukushima, Y.; Otsuka, H.; Hirakawa, J.; Mori, H.; Asano, T.; Ishikawa, T.; Katsube, T.; Ogawa, K. and Ohkawa, S. (2002) Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 16, 1811-1817.
74. Sapone, A.; Vaira, D.; Trespidi, S.; Perna, F.; Gatta, L.; Tampieri, A.; Ricci, C.; Cantelli-Forti, G.; Miglioli, M.; Biagi, G. L. and Paolini, M. (2003) The clinical role of Cytochrome P450 genotypes in Helicobacter pylori management. Am. J. Gastroenterol. 98, 1010-1015.
75. Schmid, C. H.; Whiting, G.; Cory, D.; Ross, S. D. and Chalmers, T. C. (1999) Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: a meta-regression analysis of randomized, controlled trials. Am. J. Ther. 6, 25-36.
76. Schwab, M.; Schaeffeler, E.; Klotz, U. and Treiber, G. (2004) CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin. Pharmacol. Ther. 76, 201-209.
77. Sheu, B. S.; Kao, A. W.; Cheng, H. C.; Hunag, S. F.; Chen, T. W.; Lu, C. C. and Wu, J. J. (2005) Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment. Pharmacol. Ther. 21, 283-288.
78. Shimatani, T.; Inoue, M.; Kuroiwa, T.; Horikawa, Y.; Mieno, H. and Nakamura, M. (2003) Effect of omeprazole 10 mg on intragastric pH in three different CYP2C19 genotypes, compared with omeprazole 20 mg and lafutidine 20 mg, a new H2-receptor antagonist. Aliment. Pharmacol. Ther. 18, 1149-1157.
79. Shimatani, T.; Inoue, M.; Kuroiwa, T. and Horikawa, Y. (2004) Rabeprazole 10 mg twice daily is superior to 20 mg once daily for nighttime gastric acid suppression. Aliment. Pharmacol. Ther. 19, 113-122.
80. Shirai, N.; Furuta, T.; Moriyama, Y.; Okochi, H.; Kobayashi, K.; Takashima, M.; Xiao, F.; Kosuge, K.; Nakagawa, K.; Hanai, H.; Chiba, K.; Ohashi, K. and Ishizaki, T. (2001) Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment. Pharmacol. Ther. 15, 1929-1937.
81. Shirai, N.; Furuta, T.; Xiao, F.; Kajimura, M.; Hanai, H.; Ohashi, K. and Ishizaki, T. (2002) Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and nighttime in different CYP2C19 genotype groups. Aliment. Pharmacol. Ther. 16, 837-846.
82. Sohn, D. R.; Kwon, J. T.; Kim, H. K. and Ishizaki, T. (1997) Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxilation phenotype status. Clin. Pharmacol. Ther. 61, 574-582.
83. Sugimoto, M.; Furuta, T.; Shirai, N.; Kajimura, M.; Hishida, A.; Sakurai, M.; Ohashi K. and Ishizaki, T. (2004) Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin. Pharmacol. Ther. 76, 290-301.
84. Tanaka, M.; Ohkubo, T.; Otani, K.; Suzuki, A.; Kaneko, S.; Sugawara, K.; Ryokawa, Y.; Hakusui, H.; Yamamori, S. and Ishizaki, T. (1997) Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin. Pharmacol. Ther. 62, 619-628.
85. Tanigawara, Y.; Aoyama, N.; Kita, T.; Shirakawa, K.; Komada, F.; Kasuga, M. and Okumura, K. (1999) CYP2C 19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin. Pharmacol. Ther. 66, 528-534.
86. Tucker, G. T. (1994) The interaction of proton pump inhibitors with cytochroms P450. Aliment. Pharmacol. Ther. 8, 33-38. Review.
87. Tytgat, G. N. J. (1994) Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment. Pharmacol. Ther. 8, 359-368. Review.
88. Wedlund,P. J. (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61, 174-183. Review.
89. Wrighton, S. A.; Stevens, J. C.; Becker, G. W. and Vanden Branden, M. (1993) Isolation and characterisation of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. Arch. Biochem. Biophys. 306, 240-245.
90. Xiao, Z. S.; Goldstein, J. A.; Xie, H. G.; Blaisdell, J.; Wang, W.; Jiang, C. H.; Yan, F. X.; He, N.; Huang, S. L.; Xu, Z. H. and Zhou, H. H. (1997) Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J. Pharmacol. Exp. Ther. 281, 604-609.
91. Xie, H. G.; Stein, C. M.; Kim, R. B.; Wilkinson, G. R.; Flockhart, D. A. and Wood, A. J. (1999) Allelic, genotypic and phenotypic distribution of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of Europeans throughout the world. Pharmacogenetics 9, 539-549.
92. Xie, H. G.; Kim, R. B.; Wood, A. J. and Stein, C. M. (2001) Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 921-922. Review.
93. Yamada, S.; Onda, M.; Kato, S.; Matsuda, N.; Matsuhisa, T.; Yamada, N.; Miki, M. and Matsukura, N. (2001) Genetic differences in CYP2C19 single nucleotide polymorphisms among four Asian populations. J. Gastroenterol. 36, 669-672.
94. Yasuda S.; Horai Y.; Tomono Y.; Nakai, H.; Yamato, C.; Manabe, K.; Kobayashi, K.; Chiba, K. and Ishizaki, T. (1995) Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4'-hydroxylation status. Clin. Pharmacol. Ther. 58, 143-154.